Recent Journal Updates

Cancer MedicineJun 8, 2026

Exploring the High‐Risk Factors of Gastric “Inflammatory Cancer Transformation” Based on Inflammatory Immune Response: Construction of RHPI Complicated With CAG Risk Prediction Model

Clinical Context

We think this might be relevant to the clinical guidance for Tyrer-Cuzick Model (IBIS v8).

DiabetologiaJun 5, 2026

Early glycaemic exposure and cancer risk in people with newly diagnosed type 2 diabetes

Clinical Context

We think this might be relevant to the clinical guidance for Tyrer-Cuzick Model (IBIS v8).

DiabetologiaJun 5, 2026

MASLD, diabetes and PMOS across the female life stages

Clinical Context

We think this might be relevant to the clinical guidance for Tyrer-Cuzick Model (IBIS v8).

IBIS V8Tyrer-Cuzick Risk Interpretation

Calculated Model Outputs

10-Year Breast Cancer Risk

Percent

Lifetime Breast Cancer Risk

Percent

Clinical pearl

The 20% lifetime risk threshold is a key criterion for the American Cancer Society (ACS) recommendation for annual screening Breast MRI in addition to mammography. The 10-year risk is often used to discuss chemoprevention with SERMs or Aromatase Inhibitors.

Risk Profile

22% Lifetime

Management Path

High risk. Candidate for high-risk screening (e.g., annual MRI) and discussion regarding chemoprevention (NCCN/ACS guidelines).

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Women without a prior personal history of invasive breast cancer or DCIS.

To estimate the 10-year and lifetime risk of developing breast cancer.

To identify high-risk individuals who qualify for enhanced screening (e.g., breast MRI) or chemoprevention (e.g., Tamoxifen, Anastrozole).

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the PREDICT v3.0, Oncotype DX Recurrence, RCB (Residual Cancer Burden), Z0011 Eligibility or the Tnm 8th Ed Breast Prognostic to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Recent Journal Updates

Tyrer-Cuzick (IBIS v8)

Calculated Model Outputs

22% Lifetime

When to Use

When to Use

Related Scores in Practice

Related Oncology Tools

Recent Journal Updates

Tyrer-Cuzick (IBIS v8)

Calculated Model Outputs

22% Lifetime

When to Use

When to Use

Related Scores in Practice

Related Oncology Tools